Your browser doesn't support javascript.
loading
Time-series analysis of presentations to four syringe dispensing machines and a needle and syringe programme during COVID-19 lockdowns in Melbourne, Australia.
O'Keefe, Daniel; Livingston, Michael; Cossar, Reece D; Kerr, Phoebe; Jacka, David; Dietze, Paul.
Afiliación
  • O'Keefe D; Behaviours and Health Risks Program, Burnet Institute, 85 Commercial Road, VIC, 3004, Melbourne, Australia. daniel.okeefe@burnet.edu.au.
  • Livingston M; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia. daniel.okeefe@burnet.edu.au.
  • Cossar RD; Behaviours and Health Risks Program, Burnet Institute, 85 Commercial Road, VIC, 3004, Melbourne, Australia.
  • Kerr P; Faculty of Health Sciences, National Drug Research Institute and enAble Institute, Curtin University, Perth, WA, Australia.
  • Jacka D; Centre for Alcohol Policy Research, La Trobe University, Melbourne, VIC, Australia.
  • Dietze P; Behaviours and Health Risks Program, Burnet Institute, 85 Commercial Road, VIC, 3004, Melbourne, Australia.
Harm Reduct J ; 19(1): 101, 2022 09 07.
Article en En | MEDLINE | ID: mdl-36071500
ABSTRACT

BACKGROUND:

Australian harm reduction services are provided via a mix of modalities, including fixed-site needle and syringe programmes (NSP) and syringe-dispensing machines (SDMs). SDMs are cost-effective and provide 24-h anonymous access to needles/syringes, often to underserved geographic areas, and can attract clientele who may choose not to use NSPs. The introduction of COVID-19 control measures saw disruptions and adaptations to the provision of harm reduction services. It is possible that SDMs filled the gap in otherwise disrupted harm reduction services in Melbourne. In this paper, we use data from four SDMs and an NSP to explore changes to harm reduction usage during periods of COVID-19 lockdowns in Melbourne, Australia, in 2020.

METHODS:

Our data span September 2017-December 2020. We analysed daily counts of SDM use and monthly counts of NSP use, according to unique presentations to both. Auto-regressive integrated moving average (ARIMA) time-series models were fitted to the data with the effects of lockdowns estimated via a step function.

RESULTS:

Across the study period, we estimated 85,851 SDM presentations and 29,051 NSP presentations. Usage across both the SDMs and the NSP declined during the COVID-19 lockdowns, but only the decline in SDM usage was significant in ARIMA analysis.

CONCLUSIONS:

The slight, but significant decline in SDM use suggests barriers to access, though this may have been mitigated by SDM users acquiring needles/syringes from other sources. The decline, however, may be a concern if it led to lowered needle/syringe coverage and a subsequent increase in injecting risk. Further work is needed to properly explore potential changes in preference for needle/syringe acquisition site and associated barriers. Importantly, this work adds to the body of literature around the impacts of COVID-19 on harm reduction provision and potential areas of improvement.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Abuso de Sustancias por Vía Intravenosa / COVID-19 Límite: Humans País/Región como asunto: Oceania Idioma: En Revista: Harm Reduct J Año: 2022 Tipo del documento: Article País de afiliación: Australia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Abuso de Sustancias por Vía Intravenosa / COVID-19 Límite: Humans País/Región como asunto: Oceania Idioma: En Revista: Harm Reduct J Año: 2022 Tipo del documento: Article País de afiliación: Australia